Edwards Lifesciences Corp (EW)

Receivables turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	5,724,300	5,872,600	5,999,100	6,143,400	6,004,800	5,819,000	5,657,100	5,500,800	5,382,400	5,363,800	5,355,000	5,357,100	5,232,500	5,094,500	4,925,200	4,474,200	4,386,300	4,368,700	4,321,800	4,483,700
Receivables	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Receivables turnover		—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

December 31, 2024 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $5,724,300K ÷ $—K
= —

The receivables turnover ratio for Edwards Lifesciences Corp is not available for the period from March 31, 2020, to December 31, 2024, as indicated by the data provided. The receivables turnover ratio is a measure of a company's efficiency in collecting outstanding receivables from its customers within a specific period.

A higher receivables turnover ratio is generally preferred as it indicates that the company is able to collect its accounts receivable more quickly, which may suggest effective credit policies and strong customer collections efforts. Conversely, a lower ratio may imply potential difficulties in collecting receivables or inefficient credit management practices.

Without the specific numerical values for the receivables turnover ratio for Edwards Lifesciences Corp, it is not possible to assess the company's ability to efficiently manage its accounts receivable. Further financial data would be required to evaluate this aspect of the company's financial performance in greater detail.